5-Fluorouracil, adriamycin, and mitomycin C in adenocarcinoma of the esophagus or gastroesophageal junction tumors.
We reviewed our results with chemotherapy for adenocarcinoma of the esophagus or gastroesophageal junction tumors in patients treated with 5-fluorouracil, Adriamycin, and mitomycin C (FAM) regimen as developed by MacDonald and colleagues for adenocarcinoma of the stomach. Sixteen patients were treated, 12 with metastatic and 4 with locoregional disease. Responses were seen in 6 of 16 patients (all partial responses), for an overall response rate of 37.5%. The sites of response include liver (3), lung (1), bone (1), and lymph nodes (1). Median duration of response was 7 months. These results with FAM in adenocarcinoma of the esophagus suggest activity similar to that seen in gastric carcinoma. The second-generation chemotherapy combinations effective in gastric carcinoma merit evaluation in this tumor to see if the remission rates could be further improved.
Division of Oncology, University of Mississippi School of Medicine, Jackson.
T
T
Khansur
C
C
Allred
M
M
Tavassoli
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage; D004938:Esophageal Neoplasms / Q000188:drug therapy*; D004943:Esophagogastric Junction; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D012074:Remission Induction; D016019:Survival Analysis
D016685:Mitomycin; D004317:Doxorubicin; D005472:Fluorouracil